Key result
Octreotide (0.1 mg/kg subcutaneously) failed to prevent the fall in blood pressure during head-up tilt tests in an experimental dog model of neurogenic orthostatic hypotension.
Why the study?
Does octreotide prevent the fall in blood pressure during head-up tilt in a dog model of neurogenic orthostatic hypotension?
RCT (n=12)
Double-blind
Cross-over
Does octreotide prevent the fall in blood pressure during head-up tilt in a dog model of neurogenic orthostatic hypotension?
Octreotide at 0.1 mg/kg subcutaneously is ineffective at preventing the fall in blood pressure during head-up tilt in a dog model of neurogenic orthostatic hypotension.
Answers are grounded in this paper and cite their sources.
Octreotide ineffective in this canine neurogenic OH model; leaves open efficacy in human orthostatic hypotension.
This paper investigates the effects of octreotide (0.1 mg/kg, subcutaneous) on cardiovascular adaptation during head-up tilt test in an experimental model of neurogenic orthostatic hypotension (OH) obtained by chronic sinoaortic denervation in anaesthetized dogs. Blood pressure (BP), heart rate (HR), spectral variability (Fast Fourier transformation on 512 consecutive points, delta t: 2 Hz) and plasma catecholamine levels were measured in a double blind cross-over randomized study versus placebo, in supine position and during a head-up tilt test (80 degrees, 10 min) in six sinoaortic denervated and six control (normal) dogs. In normal dogs, head-up tilt test significantly increased HR and diastolic blood pressure (DBP). Plasma noradrenaline levels and energy of the low frequency band (40-150 mHz) of systolic blood pressure (SBP) significantly increased whereas the energy of the low frequency band of HR significantly decreased. Placebo and octreotide failed to modify supine and head-up tilt values of the measured parameters (except the value of low frequency band of SBP, which increased after octreotide). In sinoaortic denervated dogs, supine values of BP, HR and plasma noradrenaline levels were significantly higher than in controls whereas the energy of the low frequency spectral band of HR and SBP was similar to controls. Head-up tilt test induced a dramatic decrease in BP. HR, plasma noradrenaline levels and energy of the low frequency band of SBP and HR remained unchanged during head-up tilt tests. Neither supine nor head-up tilt values of these parameters were modified 45 min after octreotide or placebo administration. These results show that sinoaortic denervation is a reproducible model of OH characterized by a lack of activation of sympathetic efferent pathways during head-up tilt tests. Octreotide at the dose used remains ineffective to prevent the fall in BP under these experimental conditions.
No takes yet. Share an insight, caveat, or question.
Bordet et al. (1997) conducted an RCT in Experimental neurogenic orthostatic hypotension (n=12). Octreotide vs. Placebo was evaluated on Blood pressure, heart rate, spectral variability, and plasma catecholamine levels during head-up tilt test. Octreotide (0.1 mg/kg subcutaneously) failed to prevent the fall in blood pressure during head-up tilt tests in an experimental dog model of neurogenic orthostatic hypotension.
Synapse has enriched 10 related papers. Consider them for comparative context: